Orbus Pharma Inc.

Orbus Pharma Inc.

October 25, 2005 16:41 ET

Orbus Pharma Inc. Announces Favorable Results of Fluvastatin Extended Release Bioequivalence Tests

TORONTO, ONTARIO--(CCNMatthews - Oct. 25, 2005) - Orbus Pharma Inc., (TSX:ORB) ("Orbus") today announced favorable results in its drug development of a once per day formulation for Fluvastatin, a cholesterol reducing drug.

The provisional pilot bioequivalence study has demonstrated equivalence to the brand LESCOL® (Fluvastatin Extended Release). New batches of the product to be used for regulatory submission are being manufactured in its Markham, Ontario plant. On completion of the batches, further bioequivalence studies will carried out. Orbus is currently negotiating with North American and European partnerships for the marketing of the once-a-day fluvastatin product. The Company has a patent pending covering the in house developed delivery system. Global sales in 2004 for the innovator version of the drug were over 750 million US dollars. "The once-a-day formulation of fluvastatin, incorporating a patented in house developed controlled release technology is a major milestone for Orbus and we are now confident that our product will gain regulatory approval in Europe and North America" says Jeff Renwick, President and CEO of Orbus Pharma Inc. LESCOL® is registered trademark of Novartis.

Orbus Pharma Inc., listed on The Toronto Stock Exchange under the symbol ORB, pursues a strategy of generating revenue through the licensing of our generic drug developments as well as the manufacturing and selling of pharmaceutical products.

Contact Information

  • Orbus Pharma Inc.
    Jeffrey W. Renwick
    President and C.E.O.
    (905) 943-9444 Ext 227